SNRS- Sunrise Technologies Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies

SNRS 0.000001000

0.0%

Jun 6 11:01 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob beck who wrote (2681)	7/13/1999 11:23:00 AM
From: BARRY ALLEN	of 4140

90% 90% 90% 90% 90% 90% 90% 90% 90% 90% 90% 90% 90% 90% The Company estimates that the ability to treat up to 4 diopters of hyperopia represents nearly 90% of all hyperopes* over the age of 40.* Sturza = Turdza! Still, Sturza's Medical Research analyst Stephen Sabba remains critical of the device, noting that the low levels of hyperopia that it has treated in its studies. He maintains the narrow range of diopters that the device can treat won't produce a significant demand for the product. Sturza's Institutional Research provides independent, unbiased medical technology assesments on a soft-dollar basis. These assessments are supplemented by our consulting arrangements with more than 600 clinical researchers at many of the leading research centers in the United States. July 13, 1999 07:04 AM FREMONT, Calif.--(BW HealthWire)--July 13, 1999--Sunrise Technologies International, Inc. SNRS announced that it has received conditional approval from the U.S. Food and Drug Administration (FDA) to treat, in its ongoing U.S. clinical trials, the second eye on the same day as the first eye using the Sunrise laser thermal keratoplasty (LTK) treatment for mid-hyperopia from +2.75 to +4.0 diopters. The Company estimates that the ability to treat up to 4 diopters of hyperopia represents nearly 90% of all hyperopes over the age of 40. Maybe we should contact Sturza and Avalon so they could inform their 600 clinical researchers at many of the leading research centers in the United States! info@sturzas.com research@avalonresearch.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next